Rescue

ApprovedSmall molecule

Merck & Co.

Rescue is one of 629 small molecule programs targeting Sedation. It is currently in Approved.

Indications

Total Trials

Active Trials

628

Competitors

Pipeline

Status by Indication[3][1]

Indication

Esophageal CancerActive, not recruiting

Intestinal CancerActive, not recruiting

Type 2 Diabetes MellitusActive, not recruiting

Triple-Negative Breast CancerActive, not recruiting

Chronic Obstructive Pulmonary DiseaseActive, not recruiting

Chemotherapy-Induced Nausea and VomitingActive, not recruiting

Allergic RhinitisActive, not recruiting

Esophageal AdenocarcinomaActive, not recruiting

Metastatic Prostate CancerActive, not recruiting

Non-Small Cell Lung CancerActive, not recruiting

Esophageal CancerPhase 1/Phase 2

Active, not recruiting

Intestinal CancerPhase 1/Phase 2

Active, not recruiting

Type 2 Diabetes MellitusPhase 2

Active, not recruiting

Triple-Negative Breast CancerPhase 3

Active, not recruiting

Chronic Obstructive Pulmonary DiseasePhase 2

Active, not recruiting

Chemotherapy-Induced Nausea and VomitingPhase 3

Active, not recruiting

Allergic RhinitisApproved

Active, not recruiting

Esophageal AdenocarcinomaPhase 3

Active, not recruiting

Metastatic Prostate CancerPhase 3

Active, not recruiting

Non-Small Cell Lung CancerPhase 2

Active, not recruiting

Showing 10 of 21 indications

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Rescue

Merck & Co.

Approved

44 2

Cymbalta

Alnylam Pharmaceuticals

Preclinical

3 3

MS Contin

Merck & Co.

Preclinical

2 4

Blenoxane

Bristol-Myers Squibb

Preclinical

1 5

Lexiscan

Astellas

Preclinical

1 6

Zolymbus

AbbVie

Preclinical

1 7

Nubain

AAultman Health Foundation

Preclinical

1 8

Aquasol E

NNational Eye Institute (NEI)

Preclinical

—9

QS21

MMemorial Sloan Kettering Cancer Center

Preclinical

3 10

Apatinib Mesylate

BBukwang Pharmaceutical

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

N/ANot yet recruiting

Sedation

NCT07166666

Q2 2027

Phase 3Active, not recruiting

Esophageal Adenocarcinoma

NCT06356311

Q3 2027

Phase 1Active, not recruiting

Advanced/metastatic Solid Tumors

NCT06460961

Q4 2027

Phase 2Recruiting

Malignant Neoplasm

NCT06979596

Clinical

Trials by Indication[1]

Chronic Obstructive Pulmonary Disease4 trials

Randomized Study Evaluating the Effect of Danirixin on Neutrophil Extracellular Traps (NETs) in Chronic Obstructive Pulmonary Disease (COPD)

Terminated· GSK logo

GSK·Phase 2·NCT03250689·19 enrolled

A Pilot Study of Danirixin for Disease Progression in Chronic Obstructive Pulmonary Disease (COPD)

Terminated· GSK logo

GSK·Phase 2·NCT03170232·54 enrolled

Danirixin Dose Ranging Study in Participants With Chronic Obstructive Pulmonary Disease (COPD)

Completed· GSK logo

GSK·Phase 2·NCT03034967·614 enrolled

Show 1 more trial

Study to Evaluate the Safety and Dose-Range of Navarixin (SCH 527123, MK-7123) in Participants With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (MK-7123-012)

Terminated· Merck & Co. logo

Merck & Co.·Phase 2·NCT00441701·99 enrolled

Asthma3 trials

A Study to Evaluate the Efficacy and Safety of QVM149 (Indacaterol Acetate / Glycopyrronium Bromide / Mometasone Furoate) Versus Salmeterol Xinafoate/Fluticasone Propionate in Children From 12 Years to Less Than 18 Years of Age With Asthma.

Not yet recruiting· Novartis logo

Novartis·Phase 3·NCT05776927·304 enrolled

Neutrophilic Asthma Study With Navarixin (MK-7123, SCH 527123) (MK-7123-017)(COMPLETED)

Completed· Merck & Co. logo

Merck & Co.·Phase 2·NCT00632502·37 enrolled

A Phase 2a Study to Evaluate the Effects of Sirukumab in Subjects With Severe Poorly Controlled Asthma

Withdrawn· GSK logo

GSK·Phase 2·NCT02794519

Migraine3 trials

Study of Telcagepant (MK-0974) in Participants With Moderate to Severe Acute Migraine With or Without Aura (MK-0974-011)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT00442936·1,380 enrolled

A Dose-Finding Study of MK-1602 in the Treatment of Acute Migraine (MK-1602-006)

Completed· AbbVie logo

AbbVie·Phase 2·NCT01613248·834 enrolled

A Pharmacokinetic Study of MK-1602 in the Treatment of Acute Migraine (MK-1602-007)

Completed· AbbVie logo

AbbVie·Phase 2·NCT01657370·195 enrolled

Non-Small Cell Lung Cancer2 trials

A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F)

Recruiting· Merck & Co. logo

Merck & Co.·Phase 1/2·NCT07286149·190 enrolled

A Phase 3 Randomized Open-Label Study of Adjuvant Pembrolizumab With or Without MK-2870 in Participants With Resectable Stage II to IIIB (N2) NSCLC Not Achieving pCR After Receiving Neoadjuvant Pembrolizumab With Platinum-based Doublet Chemotherapy Followed by Surgery

Recruiting· Merck & Co. logo

Merck & Co.·Phase 3·NCT06312137·780 enrolled

Bipolar Disorder2 trials

Extension Study of Asenapine [P06107 (NCT01244815)] for Pediatric Bipolar Disorder (P05898)

Completed·OOrganon and Co·Phase 3·NCT01349907·322 enrolled

Efficacy and Safety of Asenapine Treatment for Pediatric Bipolar Disorder (P06107 Has an Extension [P05898; NCT01349907])(P06107)

Completed·OOrganon and Co·Phase 3·NCT01244815·404 enrolled

28 more indications

Chemotherapy-induced nausea and vomiting2 trials

Study of Aprepitant (MK-0869) for Chemotherapy-Induced Nausea and Vomiting (CINV) in Adolescent Participants (MK-0869-097)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT00080444·50 enrolled

Efficacy and Safety of Fosaprepitant Dimeglumine in Preventing Chemotherapy-Induced Nausea and Vomiting (MK-0517-031)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT01594749·1,015 enrolled

Bladder Cancer2 trials

A Phase 3, Randomized, Open-label Study of Sacituzumab Tirumotecan (MK-2870) Versus Investigator's Choice of Non-platinum Chemotherapy in Participants With Pretreated Locally Advanced/Metastatic Urothelial Carcinoma

Recruiting· Merck & Co. logo

Merck & Co.·Phase 3·NCT07419295·590 enrolled

A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Study of Investigational Agents in Combination With Enfortumab Vedotin Plus Pembrolizumab as First-Line Treatment in Participants With Locally Advanced or Metastatic Urothelial Carcinoma: KEYMAKER-U04-Substudy 04D

Recruiting· Merck & Co. logo

Merck & Co.·Preclinical·NCT07232602·55 enrolled

Vomiting1 trial

Fosaprepitant (MK-0517, EMEND® IV) In Salvage Treatment of Chemotherapy-Induced Vomiting (MK-0517-030)

Terminated· Merck & Co. logo

Merck & Co.·Phase 2·NCT01405924·111 enrolled

Esophageal Adenocarcinoma1 trial

A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)

Active, not recruiting· Merck & Co. logo

Merck & Co.·Phase 3·NCT06356311·450 enrolled

Moderate to Severe COPD1 trial

Long-Term Study of the Effects of Navarixin (SCH 527123, MK-7123) in Participants With Moderate to Severe COPD (MK-7123-019)

Terminated· Merck & Co. logo

Merck & Co.·Phase 2·NCT01006616·616 enrolled

Type 2 Diabetes Mellitus1 trial

A Study of Different Doses of Sitagliptin (MK-0431) in Participants With Type 2 Diabetes Mellitus (MK-0431-014)

Completed· Merck & Co. logo

Merck & Co.·Phase 2·NCT00481663·555 enrolled

Cardiac Dysfunction1 trial

Strategy Therapy on Cancer Therapy-Related Cardiac Dysfunction

Unknown status·NNational Cheng-Kung University Hospital·N/A·NCT05892146·100 enrolled

Type 1 Diabetes Mellitus1 trial

A Three-part Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of MK-2640 in Healthy Participants (Part I) and Participants With Type 1 Diabetes Mellitus (Parts II and III) (MK-2640-001)

Completed· Merck & Co. logo

Merck & Co.·Phase 1·NCT02269735·74 enrolled

Advanced/Metastatic Solid Tumors1 trial

A Study of MK-6837 as a Monotherapy and Combination Therapy in Participants With Advanced/Metastatic Solid Tumors (MK-6837-001)

Active, not recruiting· Merck & Co. logo

Merck & Co.·Phase 1·NCT06460961·168 enrolled

Sedation1 trial

Study Comparing Atomizerd Midazolam & Fentanyl and Dexmedomidine for Procedural Sedation in Adult and Pediatric Patient (2 to 60 Years Old)

Not yet recruiting·OOman Medical Speciality Board·N/A·NCT07166666·128 enrolled

Allergic Rhinitis1 trial

Safety Study of MK-3641 and MK-7243 Co-administered in Adult Participants With Ragweed and Grass Pollen Induced Allergic Rhinitis (P08607, MK-3641-006)

Completed·AALK-Abelló A/S·Phase 4·NCT02256553·102 enrolled

Prostate Cancer1 trial

A Phase 3, Open-label Study of Ifinatamab Deruxtecan Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (IDeate-Prostate01)

Recruiting· Merck & Co. logo

Merck & Co.·Phase 3·NCT06925737·1,440 enrolled

Diffuse Large B-Cell Lymphoma1 trial

A Randomized, Open-Label, Multicenter, Phase 3 Study of Zilovertamab Vedotin (MK-2140) in Combination With R-CHP Versus R-CHOP in Participants With Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL) (waveLINE-010)

Recruiting· Merck & Co. logo

Merck & Co.·Phase 3·NCT06717347·1,046 enrolled

Small Cell Lung Cancer Extensive Stage1 trial

A Phase 1b/2 Open-label Study Evaluating Different MK-6070 and Ifinatamab Deruxtecan (MK-2400)-Based Regimens in First-line Extensive Stage Small Cell Lung Cancer

Recruiting· Merck & Co. logo

Merck & Co.·Preclinical·NCT07227597·170 enrolled

Malignant Neoplasm1 trial

A Multicenter, Open-label, Phase 2 Basket Study of MK-5684 in Participants With Selected Solid Tumors (OMAHA-015)

Recruiting· Merck & Co. logo

Merck & Co.·Phase 2·NCT06979596·250 enrolled

Ovarian Cancer Recurrent1 trial

A Phase 1b/2 Open-label, Multicenter Study to Evaluate the Safety and Efficacy of Raludotatug Deruxtecan With or Without Other Anticancer Investigational Agents in Participants With High-grade Serous Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Who Have Relapsed After Prior Platinum-based Chemotherapy

Recruiting· Merck & Co. logo

Merck & Co.·Preclinical·NCT06843447·460 enrolled

Lymphoma, Large B-Cell, Diffuse1 trial

A Randomized, Open-label, Multicenter, Phase 2 Study Evaluating the Efficacy and Safety of Zilovertamab Vedotin (MK-2140) Plus R-CHP Versus Polatuzumab Vedotin Plus R-CHP in Treatment-naïve Participants With GCB Subtype of Diffuse Large B-cell Lymphoma (DLBCL)

Recruiting· Merck & Co. logo

Merck & Co.·Phase 2·NCT06890884·594 enrolled

Lung Neoplasm1 trial

KEYMAKER-U01 Substudy 01I: A Phase 2, Randomized, Umbrella Study With Rolling Arms of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC)

Recruiting· Merck & Co. logo

Merck & Co.·Phase 2·NCT06780098·144 enrolled

Breast Neoplasms1 trial

A Phase 3, Randomized, Open-label Study to Evaluate the Efficacy and Safety of Sac-TMT (Sacituzumab Tirumotecan, MK-2870) Followed by Carboplatin/Paclitaxel vs Chemotherapy, Both in Combination With Pembrolizumab as Neoadjuvant Therapy for High-Risk, Early-Stage, Triple-Negative Breast Cancer or Hormone Receptor-low Positive/Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer

Recruiting· Merck & Co. logo

Merck & Co.·Phase 3·NCT06966700·2,400 enrolled

Cervical Cancer1 trial

A Phase 3, Randomized, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab With or Without Bevacizumab Compared With Standard of Care as Firstline Maintenance Treatment for Participants With Persistent, Recurrent, or Newly Diagnosed Metastatic Cervical Cancer With PD-L1 CPS Greater Than or Equal to 1 (TroFuse-036/GOG-3123/ENGOT-cx22)

Recruiting· Merck & Co. logo

Merck & Co.·Phase 3·NCT07216703·1,023 enrolled

Non Muscle Invasive Bladder Cancer1 trial

A Phase 1/2 Open-label Clinical Study to Evaluate the Safety and Efficacy of Intravesical Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (NMIBC)

Recruiting· Merck & Co. logo

Merck & Co.·Preclinical·NCT06637423·32 enrolled

Oesophageal Squamous Cell Carcinoma1 trial

A Phase 2 Open-Label, Umbrella Platform Design Study of Investigational Agent(s) in Participants With 2L/3L Unresectable Locally Advanced or Metastatic Esophageal Cancer: KEYMAKER-U06 Substudy 06F

Recruiting· Merck & Co. logo

Merck & Co.·Preclinical·NCT07405151·60 enrolled

Triple Negative Breast Neoplasms1 trial

A Phase 3, Randomized, Open-label Study Comparing Efficacy and Safety of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as a Monotherapy and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With Previously Untreated Locally Recurrent Unresectable or Metastatic Triple-Negative Breast Cancer Expressing PD-L1 at CPS Less Than 10 (TroFuse-011)

Recruiting· Merck & Co. logo

Merck & Co.·Phase 3·NCT06841354·1,000 enrolled

Gastroesophageal Adenocarcinoma1 trial

A Phase 1/2 Open-Label, Umbrella Platform Design Study to Evaluate the Safety and Efficacy of Investigational Agents in Combination With Standard of Care Treatments as the Second-Line Treatment of Participants With Advanced/Metastatic Gastroesophageal Adenocarcinoma: Substudy 06D

Recruiting· Merck & Co. logo

Merck & Co.·Preclinical·NCT06445972·210 enrolled

Ovarian Neoplasms1 trial

A Phase 3, Randomized, Open-label, Multicenter Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) Maintenance Treatment With or Without Bevacizumab Versus Standard of Care in Participants With Newly Diagnosed Advanced Non-HRD Positive Ovarian Cancer Following First-line Platinum-based Chemotherapy (TroFuse-021/ENGOTov85/GOG-3102)

Recruiting· Merck & Co. logo

Merck & Co.·Phase 3·NCT07318558·900 enrolled

Esophageal Squamous Cell Carcinoma1 trial

A Phase 1/2 Open-Label, Umbrella Platform Design Study of Investigational Agents in Combination With Pembrolizumab (MK-3475) With or Without Chemotherapy in Participants With 1L Locally Advanced Unresectable/Metastatic Esophageal Cancer: KEYMAKER-U06 Substudy 06E

Recruiting· Merck & Co. logo

Merck & Co.·Preclinical·NCT06780111·298 enrolled

Castration Resistant Prostatic Cancer1 trial

MK-2400-01A Substudy: A Phase 1/2, Open-label Umbrella Substudy of MK-2400-U01 Master Protocol to Evaluate the Safety and Efficacy of Ifinatamab Deruxtecan-based Treatment Combinations or Ifinatamab Deruxtecan Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (IDeate-Prostate02)

Recruiting· Merck & Co. logo

Merck & Co.·Preclinical·NCT06863272·360 enrolled

Colorectal Cancer1 trial

A Phase 1/2 Study to Evaluate the Safety and Efficacy of MK-2870 Monotherapy or in Combination With Other Anticancer Agents in Gastrointestinal Cancers

Recruiting· Merck & Co. logo

Merck & Co.·Preclinical·NCT06428409·220 enrolled

Sources

References

[1]
ClinicalTrials.gov — 44 trial records for Rescue. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Rescue compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Rescue. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Merck & Co. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: Merck & Co.

Rescue

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q2 2027

Q3 2027

Q4 2027

Trials by Indication[1]

Chronic Obstructive Pulmonary Disease4 trials

Asthma3 trials

Migraine3 trials

Non-Small Cell Lung Cancer2 trials

Bipolar Disorder2 trials

Chemotherapy-induced nausea and vomiting2 trials

Bladder Cancer2 trials

Vomiting1 trial

Esophageal Adenocarcinoma1 trial

Moderate to Severe COPD1 trial

Type 2 Diabetes Mellitus1 trial

Cardiac Dysfunction1 trial

Type 1 Diabetes Mellitus1 trial

Advanced/Metastatic Solid Tumors1 trial

Sedation1 trial

Allergic Rhinitis1 trial

Prostate Cancer1 trial

Diffuse Large B-Cell Lymphoma1 trial

Small Cell Lung Cancer Extensive Stage1 trial

Malignant Neoplasm1 trial

Ovarian Cancer Recurrent1 trial

Lymphoma, Large B-Cell, Diffuse1 trial

Lung Neoplasm1 trial

Breast Neoplasms1 trial

Cervical Cancer1 trial

Non Muscle Invasive Bladder Cancer1 trial

Oesophageal Squamous Cell Carcinoma1 trial

Triple Negative Breast Neoplasms1 trial

Gastroesophageal Adenocarcinoma1 trial

Ovarian Neoplasms1 trial

Esophageal Squamous Cell Carcinoma1 trial

Castration Resistant Prostatic Cancer1 trial

Colorectal Cancer1 trial

References

Drug Info

Quick Facts

Related News